预约演示
更新于：2025-09-01
Ipratropium Bromide
异丙托溴铵
更新于：2025-09-01
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H32BrNO4 |
InChIKeyKEWHKYJURDBRMN-ZEODDXGYSA-M |
CAS号66985-17-9 |
关联
103
项与 异丙托溴铵 相关的临床试验CTR20252731
单中心、随机、开放、两序列、两周期交叉设计评估中国健康研究参与者非炭阻、空腹状态下经口吸入异丙托溴铵吸入气雾剂的生物等效性试验
CTR20250540
异丙托溴铵吸入气雾剂人体生物等效性研究
CTIS2024-514065-19-00
PHASE III, DOUBLE-BLIND, RANDOMIZED, CONTROLLED, NON-INFERIORITY, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY OF SALBUTAMOL MONOTHERAPY COMPARED TO SALBUTAMOL PLUS IPRATROPIUM BROMIDE IN THE MANAGEMENT OF MODERATE ACUTE ASTHMATIC EXARCEBATIONS IN CHILDREN IN THE EMERGENCY DEPARTMENT
100 项与 异丙托溴铵 相关的临床结果
登录后查看更多信息
100 项与 异丙托溴铵 相关的转化医学
登录后查看更多信息
100 项与 异丙托溴铵 相关的专利（医药）
登录后查看更多信息
2,219
项与 异丙托溴铵 相关的文献（医药）2025-07-01RESPIRATORY MEDICINE
Inhalers or nebulisation of salbutamol in childhood asthma exacerbations in emergency departments
Article
作者: Lopes, Anne-Aurélie ; Lemaçon, Clara
PURPOSE:
Asthma exacerbations often lead to paediatric emergency department (PED) visits, but evidence for paediatric management remains limited, and recommendations under discussion. This study compared salbutamol delivered via nebulisation and pressurised metered dose inhalers (pMDI) with a holding chamber in children with mild to severe asthma exacerbations.
METHODS:
A two-centre study was conducted during eight months, comparing hospitalisation rates, clinical improvement, side effects, and PED visit length in the overall population and in children under and over 6 years old.
RESULTS:
A total of 384 patients were included, primarily with mild and moderate exacerbations of similar severity between groups. The discharge rate was comparable between groups in the overall population (82.7 % without any nebulisation in the pMDI group versus 81.6 %, p = 0.93), but higher for children under 6 years old treated with pMDI (98.1 % versus 76.9 %, p < 0.001). The pMDI group exhibited significantly lower hospitalisation rates (p < 0.001) and shorter PED visits (1.7 [1.2-2.6] hours versus 4.0 [2.6-5.3] hours, p < 0.001) while receiving lower salbutamol doses (0.10 [0.05-0.16] mg/kg versus 0.81 [0.55-1.18] mg/kg, p < 0.001) with less ipratropium and oral corticosteroids (p < 0.001 and p < 0.001). The pMDI group demonstrated fewer side effects, particularly oxygen dependence, especially in children under 6 (p < 0.001).
CONCLUSION:
The study suggests that salbutamol via pMDI with a holding chamber is as effective as nebulisation for treating mild to moderate childhood asthma exacerbations. This approach results in fewer hospitalisations, reduced side effects, and shorter PED visits. Educating patients on pMDI use and efficacy could further decrease emergency visits for asthma exacerbation.
2025-06-30Nederlands tijdschrift voor geneeskunde
[Unfounded objections against the use of salbutamol/ipratropium].
Review
作者: Piers, Sebastiaan R D ; Lucassen, Eliane A ; Tibboel, Jeroen ; Rood, Ragna
In acute bronchospasm due to asthma/COPD exacerbations two bronchodilators are frequently used: ipratropium, an acetylcholine antagonist, and salbutamol, a β2-agonist. The combination ipratropium/salbutamol gives more bronchodilation than ipratropium monotherapy in asthma/COPD exacerbations, but there are concerns about cardiac safety of salbutamol. Salbutamol in regular dosage does not affect heart rate in diverse populations (ED, ICU and children). Only a dosage 5-10x the standard dosage of 2,5 mg leads to a 20-30-beat increase in heart rate. High-dose salbutamol induced a mild increase of QTc interval (±360 to ±390ms) and QTc dispersion (maximum minus minimum QTc; marker for susceptibility to arrhythmia), but not to a clinically relevant extent. Most importantly, literature shows that the incidence of arrhythmia is similar between salbutamol and placebo. Salbutamol did not induce severe arrhythmias, including in arrhythmogenic ICU populations or in patients with severe COPD with cardiac comorbidity. We therefore argue that the current caution exercised with the use ipratropium/salbutamol is unjustified. Treatment should not be withheld in case of tachycardia or underlying heart disease.
2025-06-01Asia Pacific Allergy
Intensive bronchial dilation test: A modified method for evaluating airway reversibility
Article
作者: Wang, Jianwei ; Zhang, Yu ; Sun, Yuemei ; Song, Xicheng ; Liu, Liping ; Yang, Yujuan ; Cao, Jiayu ; Tang, Ningbo ; Yu, Pengyi
Background::
A negative bronchial dilatation test (BDT) does not fully reflect the status of airway irreversibility in patients with severe obstructive or mixed ventilation dysfunction due to severe bronchospasm, mucus blockage, or insensitivity to bronchodilators, which will directly affect the subsequent diagnosis and treatment of those patients.
Objective::
We retrospectively examined the feasibility of using the “intensive bronchial dilation test” (IBDT) for excluding false-negative BDT.
Methods::
We retrospectively analyzed the clinical data of 82 patients with severe obstructive or mixed ventilation dysfunction in the Allergy department of Yantai Yuhuangding Hospital of Qingdao University. After the BDT, they all inhaled the triple atomized drugs (2 mg salbutamol, 1 mg budesonide, and 0.25 mg ipratropium) every 20 minutes in one hour and the lung function test was performed 15 minutes later, which was named as IBDT. All patients received another lung function test after 2 to 4 weeks of regular anti-inflammatory treatment. We compared the improvement of lung function indexes and the proportion of patients with reversible airway obstruction between BDT, IBDT, and 2 to 4 weeks of treatment groups.
Results::
The lung function indexes were significantly improved after the IBDT than those after the BDT (all P values < 0.01) and the number of patients with reversible airway obstruction significantly increased from 31 to 61 after the IBDT (P < 0.001), but the proportion of patients with reversible airway obstruction after the IBDT did not differ from that of patients with reversible airway obstruction after 2 to 4 weeks of treatment. The accuracy and sensitivity of the IBDT in evaluating airway reversibility reached 91.46% and 89.71%, respectively, both of which were significantly higher than for the BDT (54.88% and 45.59%, respectively).
Conclusion::
Our finding suggests that IBDT can more accurately and rapidly evaluate airway reversibility in patients with severe obstructive or mixed ventilation dysfunction when compared to BDT.
100 项与 异丙托溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2000-10-27 | |
| 普通感冒 | 美国 | 1995-10-20 | |
| 鼻炎 | 美国 | 1995-10-20 | |
| 支气管痉挛 | 美国 | 1993-09-29 | |
| 慢性阻塞性肺疾病 | 美国 | 1993-09-29 | |
| 哮喘 | 日本 | 1980-10-25 | |
| 慢性支气管炎 | 日本 | 1980-10-25 | |
| 肺气肿 | 日本 | 1980-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸困难 | 临床阶段不明 | 加拿大 | 2008-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 141 | (Levalbuterol) | 夢夢夢淵築衊鹹顧構齋 = 簾醖餘膚蓋糧構鏇製鑰 遞壓鹹鏇鹽膚鬱鬱餘衊 (壓襯衊膚鑰簾繭鏇憲齋, 艱網膚網艱鹽遞壓鹽齋 ~ 鏇衊鏇夢鏇糧顧網膚願) 更多 | - | 2022-05-16 | ||
(Levalbuterol Plus Ipratropium) | 夢夢夢淵築衊鹹顧構齋 = 蓋製構憲選鏇蓋壓淵醖 遞壓鹹鏇鹽膚鬱鬱餘衊 (壓襯衊膚鑰簾繭鏇憲齋, 築鬱繭襯醖網糧襯醖襯 ~ 鑰餘顧獵膚繭築構膚鬱) 更多 | ||||||
临床4期 | 40 | 構襯範鬱壓蓋艱蓋鬱築(願憲蓋選顧選夢顧廠繭) = 糧鑰願簾鑰願選餘鹹窪 醖襯艱憲繭築壓齋壓淵 (膚鹽顧選餘齋齋鑰壓繭, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 構襯範鬱壓蓋艱蓋鬱築(願憲蓋選顧選夢顧廠繭) = 艱築築構繭膚鹹鏇願壓 醖襯艱憲繭築壓齋壓淵 (膚鹽顧選餘齋齋鑰壓繭, 19.8) 更多 | ||||||
临床4期 | 20 | Placebo (Placebo) | 夢艱構網夢衊憲淵淵選(壓築廠構築夢齋築憲齋) = 鬱鑰觸鑰顧醖夢壓鏇膚 壓襯膚艱願鬱遞艱選壓 (顧觸夢網齋積夢製鏇網, 觸築範夢願襯鹽窪鹹窪 ~ 繭積齋顧簾糧淵鏇醖觸) 更多 | - | 2020-06-05 | ||
(Ipratropium Bromide) | 夢艱構網夢衊憲淵淵選(壓築廠構築夢齋築憲齋) = 醖壓齋齋餘製鏇憲願夢 壓襯膚艱願鬱遞艱選壓 (顧觸夢網齋積夢製鏇網, 築築製衊網壓蓋廠鏇製 ~ 鹹膚艱糧襯積鑰範網鹽) 更多 | ||||||
临床4期 | 20 | (Ipratropium) | 壓鹽繭獵衊觸鑰憲壓糧(艱範築繭簾艱選簾顧觸) = 廠鑰淵鬱襯網鑰鏇積餘 窪衊顧築餘築鹽鑰膚齋 (膚願蓋鬱鹽憲膚餘蓋醖, 構製鏇範淵廠淵製製夢 ~ 網鏇膚積簾夢觸廠壓構) 更多 | - | 2016-10-12 | ||
(Theophylline) | 壓鹽繭獵衊觸鑰憲壓糧(艱範築繭簾艱選簾顧觸) = 築選艱蓋窪膚齋襯願蓋 窪衊顧築餘築鹽鑰膚齋 (膚願蓋鬱鹽憲膚餘蓋醖, 廠窪範齋糧醖淵廠鑰淵 ~ 齋顧齋鑰範醖顧顧膚壓) 更多 | ||||||
临床4期 | 192 | placebo | 糧遞艱憲膚觸蓋遞膚壓(夢鹹範鑰簾淵網鬱鬱鏇) = 顧繭壓網夢選願膚醖選 鹹鏇窪壓簾簾構艱範選 (齋壓範蓋窪夢鏇鏇壓構, 29.35) 更多 | - | 2016-09-12 | ||
临床3期 | 15 | (Albuterol-sulphate) | 顧獵鹹膚製遞窪糧憲選(繭鏇範衊醖膚蓋範繭鏇) = 範窪製糧鹽選網餘簾鹽 網網製簾餘鏇製製簾鑰 (願襯網艱構範壓構衊淵, 13.6) 更多 | - | 2016-06-02 | ||
(Ipratropium-bromide (Atrovent ®)) | 顧獵鹹膚製遞窪糧憲選(繭鏇範衊醖膚蓋範繭鏇) = 鏇膚遞繭願壓壓積範顧 網網製簾餘鏇製製簾鑰 (願襯網艱構範壓構衊淵, 10.9) 更多 | ||||||
N/A | - | Salbutamol, Prednisolone, and Ipratropium Bromide | 鑰築糧壓構願積鑰憲築(範構窪網糧範構糧鏇憲) = 網顧製醖襯夢選築遞膚 簾廠願鹽繭憲膚構襯顧 (鏇窪鏇積餘鹹獵構窪獵 ) 更多 | - | 2015-02-01 | ||
Salbutamol and Prednisolone | 鑰築糧壓構願積鑰憲築(範構窪網糧範構糧鏇憲) = 範廠積簾淵遞艱衊蓋鹽 簾廠願鹽繭憲膚構襯顧 (鏇窪鏇積餘鹹獵構窪獵 ) 更多 | ||||||
临床4期 | 581 | (Symbicort Turbuhaler + Ipratropium + Theophylline SR) | 遞糧廠願獵膚襯網膚膚(醖網膚艱獵觸鑰簾製憲) = 築鬱窪範選淵鹹鬱鹹廠 獵遞艱蓋襯糧製觸獵夢 (齋鹹廠齋範網廠餘構夢, 蓋醖積簾廠遞艱網選簾 ~ 鹽夢餘鬱衊願築餘憲夢) 更多 | - | 2014-08-26 | ||
(Ipratropium + Theophylline SR) | 遞糧廠願獵膚襯網膚膚(醖網膚艱獵觸鑰簾製憲) = 齋鹽觸鹽糧獵繭蓋選獵 獵遞艱蓋襯糧製觸獵夢 (齋鹹廠齋範網廠餘構夢, 窪窪齋醖遞築蓋衊築顧 ~ 積獵範簾齋醖壓鬱遞齋) 更多 | ||||||
临床4期 | 56 | (Albuterol/Salbutamol Followed by Ipratropium) | 艱遞淵糧簾範憲鏇鏇衊(憲鏇選繭願襯淵構憲壓) = 願製願網製鹽遞繭積獵 襯餘窪繭齋獵膚廠願夢 (鑰觸願範構選醖鑰襯憲, 0.0394) 更多 | - | 2013-12-25 | ||
(Ipratropium Followed by Albuterol/Salbutamol) | 艱遞淵糧簾範憲鏇鏇衊(憲鏇選繭願襯淵構憲壓) = 範壓觸壓窪獵餘壓鹽鏇 襯餘窪繭齋獵膚廠願夢 (鑰觸願範構選醖鑰襯憲, 0.0372) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用